ClinicalTrials.gg
CompletedNCT02177448Updated Jul 8, 2014

BIBR 277 Capsule in Patients With Essential Hypertension

A Phase 3 interventional study of BIBR277 low dose and BIBR277 medium dose in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
47th of 99
225 · median 184
Started
1998
with 5 others
Phase 3
40 of 99
none open now
Registered
56th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 47th largest by enrollment, is one of 6 that started in 1998, is one of 40 in phase 3, and was the 56th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The efficacy and safety of Telmisartan capsule in patients with essential hypertension were evaluated in comparison with Enalapril Maleate in the double blind trial.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥ 25 years of age
  • Patient is either male or female
  • Outpatient. Change to inpatient is not allowed during the study period
  • Blood pressure is measured 3 times or more during the 4-week observation period; the last 2 measurements in the sitting position (intervals between measurements must be less than 4 weeks) are stabilized for both of systolic pressure (within +/- 30 mmHg) and diastolic pressure within +/- 15 mmHg) with the mean exceeding 160 mmHg for systolic and 95 mmHG for diastolic pressure

Exclusion criteria

Exclusion Criteria:

  • Patient has severe hypertension (the last 2 measurements in the observation period exceed 120 mmHg in terms of diastolic blood pressure)
  • Patient has secondary or malignant hypertension
  • Patient has a history of severe cardiac failure, unstable angina, or myocardial infarction within previous six months
  • Patient has atrioventricular conduction disturbance, atrial fibrillation or severe arrhythmia
  • Patient has any symptoms of cerebrovascular disorder
  • Patient has serious hepatic dysfunction (either GOT (glutamic-oxaloacetic transaminase) or GPT (glutamic-pyruvic transaminase) exceeds 100 U)
  • Patient has renal dysfunction (serum creatinin ≥ 2.1 mg/dl)
  • Patient has uncontrolled diabetic (either of the following tests exceeds the specified standards: fasting blood glucose exceeding 151 mg/dl or exceeding 8%)
  • Patient has a history of drug sensitivity to ACE (angiotensin converting enzyme) inhibitors and angiotensin II receptor antagonists
  • Patient has a history of angioedema due to ACE inhibitors
  • Patient has hyperkalemia (K exceeding 5.5 mEq/l)
  • Patient has received enalapril just before the start of observation period
  • Patient has received treatment with any other drug(s) within three months of the start of observation period
  • Patients is pregnant, breast-feeding, or possible pregnant, or wants to be pregnant during the study period
  • Patient has any other condition that the investigator or subinvestigator feels would be inappropriate for the study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
225 participants (actual)

Study arms

  • Experimental
    BIBR277 and placebo matching enalapril

    Drug: BIBR277 low dose · Drug: BIBR277 medium dose · Drug: BIBR277 high dose · Drug: Placebo matching enalapril

  • Active comparator
    Enalapril and placebo matching BIBR277

    Drug: Enalapril low dose · Drug: Enalapril medium dose · Drug: Enalapril high dose · Drug: Placebo matching BIBR277

Interventions

06

What researchers measure

Primary outcomes

  1. Antihypertensive effect

    Time frame: every 2 weeks up to week 12

Secondary outcomes

  1. Rate of normalized blood pressure

    Time frame: every 2 weeks up to week 12

  2. Occurrence of the adverse event cough

    Time frame: up to 12 weeks

  3. Decrease in blood pressure (mean systolic and diastolic blood pressure)

    Time frame: every 2 weeks up to week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1998 and a primary completion of Sep 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2014
First posted
Jun 27, 2014
Start
Sep 1998
Primary completionActual
Sep 1999
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02177448
Responsible party
Sponsor
First posted
Jun 27, 2014
Start date
Sep 1998
Primary completion
Sep 1999
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion